Abstract:Objective To study the clinical features and recurrence factors of myelin oligodendrocyte glycoprotein (MOG) antibody disease in children and the effect of recurrence prevention regimens. Methods A retrospective analysis was performed on the medical data of 41 children with MOG antibody disease who were hospitalized in the Department of Pediatric Neurology, Xiangya Hospital of Central South University, from December 2014 to September 2020. According to the presence or absence of recurrence, they were divided into a monophasic course group (n=19) and a recurrence group (n=22). According to whether preventive treatment for recurrence was given, the children with recurrence were further divided into a preventive treatment group and a non-preventive treatment group. The clinical features were analyzed for all groups, and the annualized relapse rate (ARR) was compared before and after treatment with prevention regimens. Results For these 41 children, acute disseminated encephalomyelitis was the most common initial manifestation and was observed in 23 children (56%). Of the 41 children, 22 (54%) experienced recurrence, with 57 recurrence events in total, among which optic neuritis was the most common event (17/57, 30%). The proportion of children in the recurrence group who were treated with corticosteroids for less than 3 months in the acute phase was higher than that in the monophasic course group (64% vs 32%; P < 0.05). There was no significant difference in the ARR between the preventive treatment and non-preventive treatment groups (P > 0.05). The assessment of preventive treatment regimens for 32 cases showed that the children treated with rituximab or azathioprine had a significant reduction in the ARR during treatment (P < 0.05). Conclusions More than half of the children with MOG antibody disease may experience recurrence. Most children with recurrence are treated with corticosteroids for less than 3 months in the acute phase. Rituximab and azathioprine may reduce the risk of recurrence.
ZHU Sa-Ying,PENG Jing,MAO Lei-Lei et al. Recurrence factors for myelin oligodendrocyte glycoprotein antibody disease in children and the effect of recurrence prevention regimens[J]. CJCP, 2021, 23(7): 724-729.
Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies:a multicentre observational study[J]. Lancet Neurol, 2020, 19(3):234-246. DOI:10.1016/S1474-4422(19)30488-0. PMID:32057303.
[3]
Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders:a multicenter study of 50 patients. Part 2:epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome[J]. J Neuroinflammation, 2016, 13(1):280. DOI:10.1186/s12974-016-0718-0. PMID:27793206. PMCID:PMC5086042.
[4]
Wynford-Thomas R, Jacob A, Tomassini V. Neurological update:MOG antibody disease[J]. J Neurol, 2019, 266(5):1280-1286. DOI:10.1007/s00415-018-9122-2. PMID:30569382. PMCID:PMC6469662.
Takai Y, Misu T, Kaneko K, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease:an immunopathological study[J]. Brain, 2020, 143(5):1431-1446. DOI:10.1093/brain/awaa102. PMID:32412053.
[8]
Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis:international recommendations on diagnosis and antibody testing[J]. J Neuroinflammation, 2018, 15(1):134. DOI:10.1186/s12974-018-1144-2. PMID:29724224. PMCID:PMC5932838.
[9]
Reindl M, Jarius S, Rostasy K, et al. Myelin oligodendrocyte glycoprotein antibodies:how clinically useful are they?[J]. Curr Opin Neurol, 2017, 30(3):295-301. DOI:10.1097/WCO.0000000000000446. PMID:28248700.
[10]
de Mol CL, Wong Y, van Pelt ED, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults[J]. Mult Scler, 2020, 26(7):806-814. DOI:10.1177/1352458519845112. PMID:31094288. PMCID:PMC7294530.
Zhou J, Lu XP, Zhang Y, et al. Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination[J]. Mult Scler Relat Disord, 2019, 28:4-10. DOI:10.1016/j.msard.2018.12.001. PMID:30529926.
Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders:revisions to the 2007 definitions[J]. Mult Scler, 2013, 19(10):1261-1267. DOI:10.1177/1352458513484547. PMID:23572237.
[16]
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2):177-189. DOI:10.1212/WNL.0000000000001729. PMID:26092914. PMCID:PMC4515040.
[17]
Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination[J]. J Neurol Neurosurg Psychiatry, 2018, 89(2):127-137. DOI:10.1136/jnnp-2017-316880. PMID:29142145. PMCID:PMC5800335.
[18]
Salama S, Khan M, Shanechi A, et al. MRI differences between MOG antibody disease and AQP4 NMOSD[J]. Mult Scler, 2020, 26(14):1854-1865. DOI:10.1177/1352458519893093. PMID:31937191. PMCID:PMC7363520.
Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease[J]. JAMA Neurol, 2018, 75(4):478-487. DOI:10.1001/jamaneurol.2017.4601. PMID:29305608. PMCID:PMC5885190.